Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,486 JPY | -0.23% | +2.09% | +5.80% |
Mar. 26 | Santen Pharmaceutical to Cancel 12 Million Treasury Shares | MT |
Mar. 25 | Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023. | CI |
Sales 2024 * | 301B 1.99B | Sales 2025 * | 292B 1.93B | Capitalization | 547B 3.62B |
---|---|---|---|---|---|
Net income 2024 * | 31.42B 208M | Net income 2025 * | 33.39B 221M | EV / Sales 2024 * | 1.85 x |
Net Debt 2024 * | 10.05B 66.41M | Net cash position 2025 * | 13.82B 91.3M | EV / Sales 2025 * | 1.82 x |
P/E ratio 2024 * |
17.7
x | P/E ratio 2025 * |
16.5
x | Employees | 4,144 |
Yield 2024 * |
2.17% | Yield 2025 * |
2.31% | Free-Float | 94.9% |
1 day | -0.23% | ||
1 week | +2.09% | ||
1 month | -1.52% | ||
3 months | +6.10% | ||
6 months | +7.37% | ||
Current year | +5.80% |
Managers | Title | Age | Since |
---|---|---|---|
Takeshi Ito
CEO | Chief Executive Officer | 64 | 82-03-31 |
Kazuo Koshiji
DFI | Director of Finance/CFO | - | - |
Akira Kurokawa
CHM | Chairman | 71 | 77-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Akira Kurokawa
CHM | Chairman | 71 | 77-03-31 |
Kanoko Oishi
BRD | Director/Board Member | 63 | 15-05-31 |
Noboru Kotani
BRD | Director/Board Member | 67 | 22-06-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.22% | 14 M€ | +10.37% | ||
0.19% | 1,178 M€ | +2.26% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1,486 | -0.23% | 1 591 300 |
24-03-27 | 1,507 | +1.34% | 1,640,500 |
24-03-26 | 1,487 | +0.30% | 1,392,100 |
24-03-25 | 1,482 | +0.47% | 1,409,200 |
24-03-22 | 1,476 | +1.34% | 1,125,900 |
Delayed Quote Japan Exchange, March 28, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.80% | 3.62B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.75% | 210B | |
+1.02% | 210B | |
-6.65% | 201B | |
-3.51% | 157B |